Hospital

Data from the PERSEUS trial supports use of daratumumab in combination with bortezomib, lenalidomide, and dexamethasone followed by daratumumab and lenalidomide maintenance as a new standard of care for patients with newly diagnosed multiple myeloma.

Results from the initial safety run-in of MajesTEC-7 indicate that the combination of teclistamab, daratumumab, and lenalidomide in newly diagnosed multiple myeloma (NDMM) shows a manageable safety profile with early signs of efficacy.

Daratumumab in combination with standard treatment regimens shows benefit in multiple myeloma.

Providers, the community, health systems, and health policies can all play a part in addressing various challenges in care for obesity.

Patients with sickle cell disease with more than a 6-month delay transitioning from pediatric to adult care were about twice as likely to be hospitalized.

Data analysis can help hospitals address waste of controlled substances that fuels diversion and increased costs.

Data presented at ASCO 2024 show fam-trastuzumab deruxtecan-nxki (T-DXd) delayed cancer growth in patients with hormone receptor-positive (HR+), HER2-low or -ultralow disease that progressed following endocrine therapy (ET).

Results from the trial provide evidence bolstering ASCO’s clinical practice guideline supporting the integration of early palliative care into standard oncology practice.

The priority review of inavolisib is for treatment of patients with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation.

Women who received epidural analgesia during labor were less likely to experience severe maternal morbidity complications, such as heart attack or heart failure and sepsis.

Quadruple therapies including immunotherapy agents show promise in treating patients with multiple myeloma.

The study compares the safety and efficacy of mRNA-1345 compared to placebo.

Pediatric patients with rheumatic disease, such as systemic lupus erythematosus, mixed connective tissue disease, juvenile dermatomyositis, and systemic vasculitis are at an increased risk of serious infection.

Topline results of QWINT-2 and QWINT-4 met the primary end point of change in hemoglobin A1c compared to degludec and glargine, respectively, for those with type 2 diabetes.

A review of asthma guidelines, pharmacotherapy, and the role of the pharmacist.

Tools provide a safer testing option without using the viral proteins that cause infection.

Lisocabtagene maraleucel (Breyanzi; Bristol Myers Squibb) is a CD19-directed CAR T-cell therapy that is delivered as a one-time infusion.

Individuals from a lower socioeconomic group showed more benefits from low-dose CT screening relating to lung cancer survival.

Small steps can accumulate and have a big impact on patients’ lives

Penelope Murphy discusses the role that preceptors play in mentoring students and new pharmacists to help bridge the gap between classroom learning and real-world practice.

An inclusive apprenticeship program aligns with evolving roles, fosters growth, and positively affects patient care.

Isatuximab is used in combination with bortezomib, lenalidomide, and dexamethanose.

UC Davis Health researchers uncover substantial treatment disparities and inequal access to autologous hematopoietic cell transplantation therapy among multiple myeloma patients.

The findings demonstrated that daytime heat waves were associated with approximately 19% higher odds of asthma-related hospitalizations in children.

Speakers at the 2024 Society of Pain and Palliative Care Virtual Conference discussed advanced treatment opportunities for patients with substance use disorder (SUD) and cancer-related pain.

Continued disparities of gender representation in cardiovascular research reveal oversights that impact adequate diagnosis and treatment of cardiovascular disease in women.

The role of semaglutide as a glucagon-like peptide-1 (GLP-1) receptor antagonist could offer further treatment options to improve patient outcomes.